Abstract
Prion diseases are fatal neurodegenerative disorders that affect humans and other mammals. The hallmark of these diseases is the conformational change of the cellular prion protein (PrPC) to the misfolded protein capable of propagation and associated with neurodegeneration, named prion (PrPSc). In a strict sense, prion diseases are a consequence of aberrations in the metabolism of the cellular prion protein (PrPC). This brief review addresses current understanding of metabolic disturbances in prion disorders at the cellular, organ and organism level, selectively pointing out some relevant diagnostic and treatment options.
Keywords: Conformational diseases, metabolism, neurodegeneration, PrPC, PrPSc, transmissible spongiform encephalopathies, Prion diseases, Prion, Isoform, Glycoprotein, Misfolding proteins, Amyloid-β, PRNP gene, Translocation, Cytoplasm, Homeostasis, Olfactory discrimination, Embryogenesis, Truncations, Parkinson disease, Alzhemier disease, Tauopathies, Proteinopathies, Follicular dendritic cells, Lymphotoxin, Endocytosis, Monoclonal antibodies, Motif-grated antibodies, Epitope metabolism, ER stress, Oxidatie stress, Creutzfeldt-Jakob disease, Dementia, Myoclonus, Gerstmann-Straussler-Scheinker disease, Ataxia, Magnetic resonance spectroscopy, Pulvinar sign, Myoinositol, Gliosis, PET, Quinacrine, Swansonine, Darwinian evoluition, Anti-idiotypic antibodies
Current Drug Targets
Title: Metabolic Aspects of Prion Diseases: An Overview
Volume: 11 Issue: 10
Author(s): Tanja Vranac and Mara Bresjanac
Affiliation:
Keywords: Conformational diseases, metabolism, neurodegeneration, PrPC, PrPSc, transmissible spongiform encephalopathies, Prion diseases, Prion, Isoform, Glycoprotein, Misfolding proteins, Amyloid-β, PRNP gene, Translocation, Cytoplasm, Homeostasis, Olfactory discrimination, Embryogenesis, Truncations, Parkinson disease, Alzhemier disease, Tauopathies, Proteinopathies, Follicular dendritic cells, Lymphotoxin, Endocytosis, Monoclonal antibodies, Motif-grated antibodies, Epitope metabolism, ER stress, Oxidatie stress, Creutzfeldt-Jakob disease, Dementia, Myoclonus, Gerstmann-Straussler-Scheinker disease, Ataxia, Magnetic resonance spectroscopy, Pulvinar sign, Myoinositol, Gliosis, PET, Quinacrine, Swansonine, Darwinian evoluition, Anti-idiotypic antibodies
Abstract: Prion diseases are fatal neurodegenerative disorders that affect humans and other mammals. The hallmark of these diseases is the conformational change of the cellular prion protein (PrPC) to the misfolded protein capable of propagation and associated with neurodegeneration, named prion (PrPSc). In a strict sense, prion diseases are a consequence of aberrations in the metabolism of the cellular prion protein (PrPC). This brief review addresses current understanding of metabolic disturbances in prion disorders at the cellular, organ and organism level, selectively pointing out some relevant diagnostic and treatment options.
Export Options
About this article
Cite this article as:
Vranac Tanja and Bresjanac Mara, Metabolic Aspects of Prion Diseases: An Overview, Current Drug Targets 2010; 11 (10) . https://dx.doi.org/10.2174/1389450111007011207
DOI https://dx.doi.org/10.2174/1389450111007011207 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Motor Neuron Disease and Acquired Axonal Neuropathy Association in HIV Infection: Case Report and Update
Current HIV Research Expression Profiles of MicroRNAs in Stem Cells Differentiation
Current Pharmaceutical Biotechnology Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design Allosteric Modulation of Nicotinic Acetylcholine Receptors: The Concept and Therapeutic Trends
Current Pharmaceutical Design Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines
Current Drug Targets Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design The Neurotrophins and Their Role in Alzheimers Disease
Current Neuropharmacology Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers
Current Alzheimer Research Oral Administration of Thioflavin T Prevents Beta Amyloid Plaque Formation in Double Transgenic AD Mice
Current Alzheimer Research Stress-Induced Oxidative Changes in Brain
CNS & Neurological Disorders - Drug Targets Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry Neuroglial Roots of Neurodegenerative Diseases: Therapeutic Potential of Palmitoylethanolamide in Models of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets DL-3-n-Butylphthalide, an Anti-Oxidant Agent, Prevents Neurological Deficits and Cerebral Injury Following Stroke per Functional Analysis, Magnetic Resonance Imaging and Histological Assessment
Current Neurovascular Research Fighting Against Alzheimer's Disease: Synthesis of New Pyrazoline and Benzothiazole Derivatives as New Acetylcholinesterase and MAO Inhibitors
Letters in Drug Design & Discovery Editorial [Medicinal Chemistry of Novel Therapeutics (Guest Editor: Tanaji Talele)]
Current Bioactive Compounds Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening
Medicinal Chemistry Pathophysiology of Transmissible Spongiform Encephalopathies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents